Life-Extending drug access granted for rare blood disorder patients
NCT ID NCT05221619
Summary
This program provides continued access to the drug nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who benefited from it in a previous 28-week study. It is for participants who showed improvement in their hemoglobin levels and completed the prior study without needing rescue treatment. The goal is to allow these patients to keep receiving a treatment that is helping control their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.